Sibrotuzumab

Sibrotuzumab
Monoclonal antibody
Type Whole antibody
Source Humanized (from mouse)
Target FAP
Identifiers
CAS Number 216669-97-5 N
ATC code None
ChemSpider none
 NYesY (what is this?)  (verify)

Sibrotuzumab is a humanized monoclonal antibody intended for the treatment of cancer. It binds to FAP[1][2]

In 2003 it failed a phase II clinical trial for metastatic colorectal cancer.[3]

References

  1. Scott, AM; Wiseman, G; Welt, S; Adjei, A; Lee, FT; Hopkins, W; Divgi, CR; Hanson, LH; et al. (2003). "A Phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer". Clinical cancer research : an official journal of the American Association for Cancer Research 9 (5): 1639–47. PMID 12738716.
  2. Kloft, C; Graefe, EU; Tanswell, P; Scott, AM; Hofheinz, R; Amelsberg, A; Karlsson, MO (2004). "Population pharmacokinetics of sibrotuzumab, a novel therapeutic monoclonal antibody, in cancer patients". Investigational new drugs 22 (1): 39–52. doi:10.1023/B:DRUG.0000006173.72210.1c. PMID 14707493.
  3. Stromal antigen targeting by a humanised monoclonal antibody: an early phase II trial of sibrotuzumab in patients with metastatic colorectal cancer.


This article is issued from Wikipedia - version of the Thursday, November 19, 2015. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.